Literature DB >> 26243370

Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004.

Franck Raeppel1, Stéphane L Raeppel2, Eric Therrien1.   

Abstract

New heteroarylcarboxamide head groups substituted with two aromatic rings analogs of thieno[3,2-b]pyridine-based kinase inhibitor LCRF-0004 were designed and synthesized. Potent inhibitors of RON tyrosine kinase with various level of selectivity for c-Met RTK were obtained.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Head group; Molecular docking; Oncology; RON; RON homology model; RTK inhibitors; c-Met

Mesh:

Substances:

Year:  2015        PMID: 26243370     DOI: 10.1016/j.bmcl.2015.07.080

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

2.  Short-form Ron is a novel determinant of ovarian cancer initiation and progression.

Authors:  Katherine M Moxley; Luyao Wang; Alana L Welm; Magdalena Bieniasz
Journal:  Genes Cancer       Date:  2016-05

3.  When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Authors:  Anne-Marie Baird; David Easty; Monika Jarzabek; Liam Shiels; Alex Soltermann; Sonja Klebe; Stéphane Raeppel; Lauren MacDonagh; Chengguang Wu; Kim Griggs; Michaela B Kirschner; Bryan Stanfill; Daisuke Nonaka; Chandra M Goparaju; Bruno Murer; Dean A Fennell; Dearbhaile M O'Donnell; Martin P Barr; Luciano Mutti; Glen Reid; Stephen Finn; Sinead Cuffe; Harvey I Pass; Isabelle Opitz; Annette T Byrne; Kenneth J O'Byrne; Steven G Gray
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-26       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.